Share Price and Basic Stock Data
Last Updated: November 15, 2025, 2:33 pm
| PEG Ratio | 1.22 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Genesys International Corporation Ltd operates in the IT Consulting and Software sector and has reported a current price of ₹514 with a market capitalization of ₹2,146 Cr. The company’s revenue has shown a notable upward trend, with sales rising from ₹120 Cr in March 2022 to ₹181 Cr in March 2023, and projected sales for March 2025 standing at ₹311 Cr. This growth trajectory is indicative of strong demand for its services and effective business strategies. Quarterly sales figures have also fluctuated, with the highest recorded sales of ₹94.16 Cr in March 2025, showcasing a robust increase compared to ₹34.55 Cr in June 2023. The company’s ability to adapt to market dynamics and capitalize on emerging trends has been a crucial factor in this revenue growth, enabling it to achieve a trailing twelve months (TTM) revenue of ₹326 Cr.
Profitability and Efficiency Metrics
Genesys International has reported an operating profit margin (OPM) of 41.63%, reflecting its efficient cost management and pricing strategies. The company recorded an operating profit of ₹143 Cr for the fiscal year ending March 2025, which translates to an OPM of 46% on the total sales of ₹311 Cr. However, the profitability has shown some volatility, with a dip in net profit to ₹-5.46 Cr in June 2023 before rebounding to ₹19 Cr by March 2025. The return on equity (ROE) stands at 10.8%, while the return on capital employed (ROCE) is at 15.0%, indicating a solid ability to generate returns for shareholders. The interest coverage ratio (ICR) is strong at 16.68x, which suggests that the company can comfortably meet its interest obligations, enhancing its financial stability.
Balance Sheet Strength and Financial Ratios
Genesys International’s balance sheet reflects a prudent financial strategy, with total borrowings reported at ₹122 Cr against reserves of ₹536 Cr, establishing a healthy reserves-to-borrowings ratio. The debt-to-equity ratio stands at 0.19, indicating low leverage compared to industry norms, which typically range higher, showcasing the company’s conservative borrowing strategy. The company has a current ratio of 2.41, well above the typical benchmark of 1.5, suggesting strong short-term liquidity. Additionally, the price-to-book value (P/BV) ratio is at 5.15x, which is relatively high compared to sector averages, potentially indicating overvaluation or strong market sentiment. The enterprise value (EV) of ₹2,956.65 Cr further underscores the company’s robust market position.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genesys International reveals a diverse ownership structure, with the public holding 62.27% of shares as of March 2025, indicating robust retail investor confidence. Promoters hold 31.55%, down from 40.60% in December 2022, suggesting a gradual dilution of control, which may be perceived positively by investors seeking transparency. Foreign institutional investors (FIIs) hold 4.69%, while domestic institutional investors (DIIs) hold 1.47%, reflecting limited institutional participation. The number of shareholders has grown significantly, increasing from 7,401 in December 2022 to 45,192 in March 2025, which indicates rising interest and confidence in the company’s prospects among retail investors. This broadening of the shareholder base could enhance liquidity and stability in the stock price.
Outlook, Risks, and Final Insight
The outlook for Genesys International appears positive, driven by its strong revenue growth and profitability metrics. However, the company faces risks including potential volatility in quarterly earnings, as evidenced by the sharp decline in net profit in mid-2023. Additionally, the decreasing promoter stake could raise concerns over long-term strategic direction, potentially affecting investor sentiment. Another risk is the high P/BV ratio, which may indicate overvaluation if growth expectations are not met. Conversely, the company’s solid balance sheet, low debt levels, and strong liquidity position mitigate financial risks. To maintain momentum, Genesys may need to focus on sustaining operational efficiencies and enhancing shareholder value while navigating market challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesys International Corporation Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Naapbooks Ltd | 167 Cr. | 155 | 194/99.8 | 25.6 | 36.4 | 0.00 % | 23.6 % | 17.1 % | 10.0 |
| IB Infotech Enterprises Ltd | 33.3 Cr. | 260 | 310/140 | 23.8 | 26.7 | 0.38 % | 38.5 % | 35.4 % | 10.0 |
| Hit Kit Global Solutions Ltd | 6.31 Cr. | 1.29 | 1.73/0.91 | 2.47 | 0.00 % | 2.14 % | 2.15 % | 2.00 | |
| Globalspace Technologies Ltd | 57.5 Cr. | 16.7 | 25.0/14.3 | 103 | 15.8 | 0.00 % | 2.13 % | 1.41 % | 10.0 |
| First Fintec Ltd | 7.26 Cr. | 6.98 | 11.7/5.25 | 90.8 | 10.3 | 0.00 % | 0.28 % | 0.85 % | 10.0 |
| Industry Average | 19,847.45 Cr | 579.18 | 94.24 | 125.02 | 0.55% | 14.92% | 20.41% | 6.95 |
All Competitor Stocks of Genesys International Corporation Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.69 | 37.38 | 54.43 | 46.62 | 34.55 | 33.19 | 59.34 | 71.17 | 55.76 | 72.02 | 89.09 | 94.16 | 70.87 |
| Expenses | 30.95 | 26.42 | 35.07 | 30.30 | 28.75 | 25.49 | 28.56 | 34.92 | 35.35 | 42.64 | 46.52 | 44.39 | 41.37 |
| Operating Profit | 11.74 | 10.96 | 19.36 | 16.32 | 5.80 | 7.70 | 30.78 | 36.25 | 20.41 | 29.38 | 42.57 | 49.77 | 29.50 |
| OPM % | 27.50% | 29.32% | 35.57% | 35.01% | 16.79% | 23.20% | 51.87% | 50.93% | 36.60% | 40.79% | 47.78% | 52.86% | 41.63% |
| Other Income | 1.37 | 1.93 | 1.79 | 1.41 | 0.93 | 1.11 | 2.53 | 0.46 | 1.41 | 1.00 | 1.84 | 0.11 | 1.27 |
| Interest | 0.54 | 0.56 | 0.35 | 1.22 | 0.67 | 0.72 | 1.09 | 1.43 | 1.24 | 1.88 | 2.58 | 3.08 | 3.18 |
| Depreciation | 8.14 | 8.90 | 9.30 | 10.86 | 11.30 | 10.94 | 11.06 | 11.18 | 11.80 | 12.25 | 15.69 | 15.29 | 15.43 |
| Profit before tax | 4.43 | 3.43 | 11.50 | 5.65 | -5.24 | -2.85 | 21.16 | 24.10 | 8.78 | 16.25 | 26.14 | 31.51 | 12.16 |
| Tax % | 55.53% | 5.83% | 32.70% | 64.42% | 4.39% | 20.70% | 25.71% | 38.63% | 39.64% | 31.69% | 20.73% | 39.73% | 42.60% |
| Net Profit | 1.97 | 3.23 | 7.73 | 2.00 | -5.46 | -3.43 | 15.73 | 14.79 | 5.30 | 11.09 | 20.71 | 19.00 | 6.98 |
| EPS in Rs | 1.36 | 1.30 | 2.13 | 0.57 | -1.41 | -0.87 | 4.19 | 3.76 | 1.36 | 2.83 | 5.20 | 4.76 | 1.71 |
Last Updated: August 20, 2025, 10:30 am
Below is a detailed analysis of the quarterly data for Genesys International Corporation Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 70.87 Cr.. The value appears to be declining and may need further review. It has decreased from 94.16 Cr. (Mar 2025) to 70.87 Cr., marking a decrease of 23.29 Cr..
- For Expenses, as of Jun 2025, the value is 41.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 44.39 Cr. (Mar 2025) to 41.37 Cr., marking a decrease of 3.02 Cr..
- For Operating Profit, as of Jun 2025, the value is 29.50 Cr.. The value appears to be declining and may need further review. It has decreased from 49.77 Cr. (Mar 2025) to 29.50 Cr., marking a decrease of 20.27 Cr..
- For OPM %, as of Jun 2025, the value is 41.63%. The value appears to be declining and may need further review. It has decreased from 52.86% (Mar 2025) to 41.63%, marking a decrease of 11.23%.
- For Other Income, as of Jun 2025, the value is 1.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Mar 2025) to 1.27 Cr., marking an increase of 1.16 Cr..
- For Interest, as of Jun 2025, the value is 3.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.08 Cr. (Mar 2025) to 3.18 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 15.43 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.29 Cr. (Mar 2025) to 15.43 Cr., marking an increase of 0.14 Cr..
- For Profit before tax, as of Jun 2025, the value is 12.16 Cr.. The value appears to be declining and may need further review. It has decreased from 31.51 Cr. (Mar 2025) to 12.16 Cr., marking a decrease of 19.35 Cr..
- For Tax %, as of Jun 2025, the value is 42.60%. The value appears to be increasing, which may not be favorable. It has increased from 39.73% (Mar 2025) to 42.60%, marking an increase of 2.87%.
- For Net Profit, as of Jun 2025, the value is 6.98 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 6.98 Cr., marking a decrease of 12.02 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.71. The value appears to be declining and may need further review. It has decreased from 4.76 (Mar 2025) to 1.71, marking a decrease of 3.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:21 am
| Metric | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 95 | 60 | 47 | 64 | 114 | 115 | 112 | 80 | 120 | 181 | 198 | 311 | 331 |
| Expenses | 42 | 47 | 40 | 48 | 78 | 96 | 98 | 81 | 92 | 122 | 117 | 168 | 179 |
| Operating Profit | 53 | 13 | 7 | 16 | 36 | 19 | 13 | -2 | 28 | 59 | 81 | 143 | 152 |
| OPM % | 56% | 21% | 16% | 25% | 32% | 17% | 12% | -2% | 23% | 32% | 41% | 46% | 46% |
| Other Income | -1 | 2 | 6 | 3 | 4 | 3 | 4 | -30 | -42 | 6 | 5 | 4 | 7 |
| Interest | 0 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 5 | 10 | 12 |
| Depreciation | 7 | 8 | 7 | 13 | 14 | 19 | 21 | 19 | 19 | 37 | 44 | 55 | 62 |
| Profit before tax | 45 | 5 | 5 | 5 | 24 | 0 | -7 | -54 | -36 | 25 | 37 | 83 | 85 |
| Tax % | -1% | 11% | 6% | -41% | 28% | 1,108% | -23% | -5% | 11% | 40% | 42% | 32% | |
| Net Profit | 46 | 4 | 2 | 6 | 17 | -4 | -5 | -52 | -40 | 15 | 22 | 56 | 59 |
| EPS in Rs | 15.42 | 1.43 | 0.73 | 2.11 | 5.50 | 1.73 | 0.61 | -13.75 | 4.28 | 5.05 | 5.58 | 14.12 | 14.55 |
| Dividend Payout % | 8% | 9% | 17% | 6% | 2% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 183.33% | -123.53% | -25.00% | -940.00% | 23.08% | 137.50% | 46.67% | 154.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | -16.67% | -306.86% | 98.53% | -915.00% | 963.08% | 114.42% | -90.83% | 107.88% |
Genesys International Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 38% |
| TTM: | 49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 98% |
| 3 Years: | -3% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 63% |
| 3 Years: | 1% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 4:40 am
Balance Sheet
Last Updated: November 9, 2025, 2:03 pm
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 19 | 20 | 20 |
| Reserves | 126 | 193 | 195 | 152 | 209 | 208 | 197 | 158 | 189 | 387 | 469 | 536 |
| Borrowings | 2 | 12 | 14 | 22 | 24 | 26 | 16 | 14 | 26 | 39 | 60 | 122 |
| Other Liabilities | 23 | 25 | 37 | 135 | 136 | 134 | 136 | 117 | 88 | 61 | 86 | 100 |
| Total Liabilities | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 |
| Fixed Assets | 46 | 21 | 22 | 179 | 217 | 208 | 203 | 194 | 138 | 157 | 156 | 128 |
| CWIP | -0 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | 19 | 65 | 113 | 156 |
| Investments | 8 | 122 | 156 | 25 | 11 | 11 | 15 | 8 | 6 | 51 | -0 | -0 |
| Other Assets | 111 | 101 | 84 | 120 | 157 | 165 | 147 | 102 | 156 | 232 | 366 | 495 |
| Total Assets | 165 | 244 | 262 | 324 | 385 | 383 | 365 | 304 | 319 | 506 | 635 | 778 |
Below is a detailed analysis of the balance sheet data for Genesys International Corporation Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 20.00 Cr..
- For Reserves, as of Mar 2025, the value is 536.00 Cr.. The value appears strong and on an upward trend. It has increased from 469.00 Cr. (Mar 2024) to 536.00 Cr., marking an increase of 67.00 Cr..
- For Borrowings, as of Mar 2025, the value is 122.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 60.00 Cr. (Mar 2024) to 122.00 Cr., marking an increase of 62.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 100.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 86.00 Cr. (Mar 2024) to 100.00 Cr., marking an increase of 14.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 778.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 635.00 Cr. (Mar 2024) to 778.00 Cr., marking an increase of 143.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 128.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2024) to 128.00 Cr., marking a decrease of 28.00 Cr..
- For CWIP, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 43.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 495.00 Cr.. The value appears strong and on an upward trend. It has increased from 366.00 Cr. (Mar 2024) to 495.00 Cr., marking an increase of 129.00 Cr..
- For Total Assets, as of Mar 2025, the value is 778.00 Cr.. The value appears strong and on an upward trend. It has increased from 635.00 Cr. (Mar 2024) to 778.00 Cr., marking an increase of 143.00 Cr..
Notably, the Reserves (536.00 Cr.) exceed the Borrowings (122.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 51.00 | 1.00 | -7.00 | -6.00 | 12.00 | -7.00 | -3.00 | -16.00 | 2.00 | 20.00 | 21.00 | 21.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 343 | 219 | 132 | 134 | 186 | 155 | 148 | 150 | 168 | 263 | 261 |
| Working Capital Days | 172 | 326 | 172 | 105 | 99 | 215 | 223 | 126 | 82 | 212 | 269 | 291 |
| ROCE % | 41% | 3% | 3% | 8% | 1% | -1% | -7% | 4% | 7% | 8% | 15% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 14.14 | 5.78 | 5.44 | 4.28 | -13.77 |
| Diluted EPS (Rs.) | 14.03 | 5.74 | 5.29 | 4.28 | -13.34 |
| Cash EPS (Rs.) | 27.92 | 16.72 | 13.81 | -6.55 | -10.57 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 139.57 | 124.12 | 107.93 | 75.21 | 81.64 |
| Revenue From Operations / Share (Rs.) | 78.14 | 50.14 | 47.97 | 38.14 | 25.48 |
| PBDIT / Share (Rs.) | 36.80 | 21.64 | 17.18 | 9.83 | -0.49 |
| PBIT / Share (Rs.) | 22.98 | 10.39 | 7.33 | 3.74 | -6.51 |
| PBT / Share (Rs.) | 20.77 | 9.40 | 6.62 | -11.44 | -17.43 |
| Net Profit / Share (Rs.) | 14.10 | 5.47 | 3.95 | -12.65 | -16.59 |
| NP After MI And SOA / Share (Rs.) | 14.13 | 5.58 | 5.05 | 4.28 | -13.75 |
| PBDIT Margin (%) | 47.09 | 43.16 | 35.81 | 25.78 | -1.95 |
| PBIT Margin (%) | 29.40 | 20.72 | 15.27 | 9.79 | -25.53 |
| PBT Margin (%) | 26.58 | 18.75 | 13.79 | -29.98 | -68.43 |
| Net Profit Margin (%) | 18.03 | 10.90 | 8.24 | -33.17 | -65.09 |
| NP After MI And SOA Margin (%) | 18.07 | 11.13 | 10.53 | 11.21 | -53.96 |
| Return on Networth / Equity (%) | 10.12 | 4.51 | 4.70 | 6.54 | -24.77 |
| Return on Capital Employeed (%) | 15.53 | 7.81 | 6.33 | 4.76 | -7.59 |
| Return On Assets (%) | 7.22 | 3.47 | 3.77 | 4.17 | -14.11 |
| Long Term Debt / Equity (X) | 0.02 | 0.04 | 0.04 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.19 | 0.10 | 0.07 | 0.09 | 0.03 |
| Asset Turnover Ratio (%) | 0.44 | 0.34 | 0.43 | 0.41 | 0.23 |
| Current Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Quick Ratio (X) | 2.41 | 3.04 | 3.52 | 1.73 | 2.13 |
| Interest Coverage Ratio (X) | 16.68 | 21.89 | 24.33 | 12.45 | -0.53 |
| Interest Coverage Ratio (Post Tax) (X) | 7.39 | 6.53 | 6.60 | 3.19 | -6.06 |
| Enterprise Value (Cr.) | 2956.65 | 2312.97 | 1258.23 | 1817.61 | 404.10 |
| EV / Net Operating Revenue (X) | 9.51 | 11.67 | 6.95 | 15.19 | 5.08 |
| EV / EBITDA (X) | 20.18 | 27.03 | 19.40 | 58.93 | -260.36 |
| MarketCap / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| Price / BV (X) | 5.15 | 4.78 | 3.06 | 8.73 | 1.84 |
| Price / Net Operating Revenue (X) | 9.21 | 11.78 | 6.86 | 14.95 | 4.02 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | -0.13 |
After reviewing the key financial ratios for Genesys International Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 14.14. This value is within the healthy range. It has increased from 5.78 (Mar 24) to 14.14, marking an increase of 8.36.
- For Diluted EPS (Rs.), as of Mar 25, the value is 14.03. This value is within the healthy range. It has increased from 5.74 (Mar 24) to 14.03, marking an increase of 8.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 27.92. This value is within the healthy range. It has increased from 16.72 (Mar 24) to 27.92, marking an increase of 11.20.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 139.57. It has increased from 124.12 (Mar 24) to 139.57, marking an increase of 15.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 78.14. It has increased from 50.14 (Mar 24) to 78.14, marking an increase of 28.00.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.80. This value is within the healthy range. It has increased from 21.64 (Mar 24) to 36.80, marking an increase of 15.16.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.98. This value is within the healthy range. It has increased from 10.39 (Mar 24) to 22.98, marking an increase of 12.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 20.77. This value is within the healthy range. It has increased from 9.40 (Mar 24) to 20.77, marking an increase of 11.37.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 14.10. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 14.10, marking an increase of 8.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 14.13. This value is within the healthy range. It has increased from 5.58 (Mar 24) to 14.13, marking an increase of 8.55.
- For PBDIT Margin (%), as of Mar 25, the value is 47.09. This value is within the healthy range. It has increased from 43.16 (Mar 24) to 47.09, marking an increase of 3.93.
- For PBIT Margin (%), as of Mar 25, the value is 29.40. This value exceeds the healthy maximum of 20. It has increased from 20.72 (Mar 24) to 29.40, marking an increase of 8.68.
- For PBT Margin (%), as of Mar 25, the value is 26.58. This value is within the healthy range. It has increased from 18.75 (Mar 24) to 26.58, marking an increase of 7.83.
- For Net Profit Margin (%), as of Mar 25, the value is 18.03. This value exceeds the healthy maximum of 10. It has increased from 10.90 (Mar 24) to 18.03, marking an increase of 7.13.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 18.07. This value is within the healthy range. It has increased from 11.13 (Mar 24) to 18.07, marking an increase of 6.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.12. This value is below the healthy minimum of 15. It has increased from 4.51 (Mar 24) to 10.12, marking an increase of 5.61.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.53. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 15.53, marking an increase of 7.72.
- For Return On Assets (%), as of Mar 25, the value is 7.22. This value is within the healthy range. It has increased from 3.47 (Mar 24) to 7.22, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.19, marking an increase of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.34 (Mar 24) to 0.44, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Quick Ratio (X), as of Mar 25, the value is 2.41. This value exceeds the healthy maximum of 2. It has decreased from 3.04 (Mar 24) to 2.41, marking a decrease of 0.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 16.68. This value is within the healthy range. It has decreased from 21.89 (Mar 24) to 16.68, marking a decrease of 5.21.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.39. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 7.39, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,956.65. It has increased from 2,312.97 (Mar 24) to 2,956.65, marking an increase of 643.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.51. This value exceeds the healthy maximum of 3. It has decreased from 11.67 (Mar 24) to 9.51, marking a decrease of 2.16.
- For EV / EBITDA (X), as of Mar 25, the value is 20.18. This value exceeds the healthy maximum of 15. It has decreased from 27.03 (Mar 24) to 20.18, marking a decrease of 6.85.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For Price / BV (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has increased from 4.78 (Mar 24) to 5.15, marking an increase of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.21. This value exceeds the healthy maximum of 3. It has decreased from 11.78 (Mar 24) to 9.21, marking a decrease of 2.57.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesys International Corporation Ltd:
- Net Profit Margin: 18.03%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.53% (Industry Average ROCE: 14.92%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.12% (Industry Average ROE: 20.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.39
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.8 (Industry average Stock P/E: 94.24)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 18.03%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| IT Consulting & Software | 73-A, SDF-III, SEEPZ, Mumbai Maharashtra 400096 | investors@igenesys.com http://www.igenesys.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sajid Malik | Chairman & Managing Director |
| Ms. Bharti Sinha | Independent Director |
| Mr. Manish Patel | Independent Director |
| Mr. Ajay Aggarwal | Independent Director |
| Mr. Omprakash Hemrajani | Director |
| Dr. Yogita Shukla | Director |
FAQ
What is the intrinsic value of Genesys International Corporation Ltd?
Genesys International Corporation Ltd's intrinsic value (as of 16 November 2025) is 488.51 which is 2.63% higher the current market price of 476.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,985 Cr. market cap, FY2025-2026 high/low of 1,055/455, reserves of ₹536 Cr, and liabilities of 778 Cr.
What is the Market Cap of Genesys International Corporation Ltd?
The Market Cap of Genesys International Corporation Ltd is 1,985 Cr..
What is the current Stock Price of Genesys International Corporation Ltd as on 16 November 2025?
The current stock price of Genesys International Corporation Ltd as on 16 November 2025 is 476.
What is the High / Low of Genesys International Corporation Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesys International Corporation Ltd stocks is 1,055/455.
What is the Stock P/E of Genesys International Corporation Ltd?
The Stock P/E of Genesys International Corporation Ltd is 33.8.
What is the Book Value of Genesys International Corporation Ltd?
The Book Value of Genesys International Corporation Ltd is 164.
What is the Dividend Yield of Genesys International Corporation Ltd?
The Dividend Yield of Genesys International Corporation Ltd is 0.00 %.
What is the ROCE of Genesys International Corporation Ltd?
The ROCE of Genesys International Corporation Ltd is 15.0 %.
What is the ROE of Genesys International Corporation Ltd?
The ROE of Genesys International Corporation Ltd is 10.8 %.
What is the Face Value of Genesys International Corporation Ltd?
The Face Value of Genesys International Corporation Ltd is 5.00.